The FDA has expanded labels for Vertex’s ALYFTREK and TRIKAFTA, enabling treatment for nearly 95% of cystic fibrosis patients through a broader, response-based eligibility approach.
Written By: Sana Khan, BPharm
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration has approved label expansions for ALYFTREK and TRIKAFTA, two CFTR modulators developed by Vertex Pharmaceuticals. This milestone is expected to expand treatment access to approximately 95% of individuals living with Cystic Fibrosis (CF) in the United States.
Cystic Fibrosis is a life-threatening genetic disorder that primarily affects the lungs and digestive system. It is caused by mutations in the CFTR gene, resulting in thick mucus buildup, chronic lung infections, and multi-organ complications. CFTR modulators such as ALYFTREK and TRIKAFTA work by restoring CFTR protein function, addressing the underlying cause of disease rather than symptoms.
Previously, these therapies were limited to patients with a defined list of CFTR mutations shown to respond in clinical studies, this leaves patients with rarer variants out of reach from these therapies. With the latest update, the U.S. Food and Drug Administration has adopted a broader eligibility approach based on biological response.
The updated labels now allow use of ALYFTREK in patients aged 6 years and older and TRIKAFTA in patients aged 2 years and older, shifting eligibility from a fixed mutation list to a response-based approach rather than the specific mutation carried. Patients are now eligible if their CFTR mutation has been shown to respond in clinical or laboratory studies, or if it produces CFTR protein that can be targeted by these therapies.
As a result, approximately 800 additional patients in the U.S. become eligible for CFTR modulator therapy, bringing overall eligibility to nearly 95% of the cystic fibrosis population.
Safety remains an important consideration. Both therapies carry warnings for drug-induced liver injury, including rare cases of liver failure. Regular liver function monitoring is recommended, particularly during the first 18 months of treatment. Additional risks include hypersensitivity reactions, neuropsychiatric events, and potential drug interactions, especially with CYP3A modulators.
Commenting on the approval, Carmen Bozic, Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex Pharmaceuticals, stated that the milestone reflects more than two decades of research, including extensive mutation testing, large clinical trials, and expansion into younger patients. She added that the updated labels now include any mutation that produces CFTR protein and demonstrates responsiveness, marking a shift toward a broader, mechanism-based treatment approach.
The label expansion is supported by clinical and in vitro evidence demonstrating responsiveness across 564 CFTR variants for ALYFTREK and 521 variants for TRIKAFTA, enabling this broader eligibility approach.
Reference:
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People with CF in the United States, 01 April 2026, https://news.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-approval-label-extensions-alyftrekr-and
About the Writer
Sana Jamil Khan is a B.Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.